Stay updated with the latest antibody-drug-conjugate news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on antibody-drug-conjugate topics.
Hyderabad: Laurus Labs on Thursday said it saw an 875% jump in consolidated net profit for the second quarter ended Sept 30, 2025, at ₹195 crore from ₹20 crore in the same quarter of the last financial year. The company's revenues climbed 35% year-on-year to ₹1,653 crore compared to ₹1,224 crore in Q2FY25.The company attributed the surge in profits and revenues to its expanding contract development and manufacturing organisation (CDMO) business and strong performance in generics, underpinned by ...Read More >
New Delhi [India], August 25 (ANI): India's contract research, development, and manufacturing organisation (CRDMO) sector is emerging as one of the most dynamic growth stories in the global pharmaceutical landscape. According to a recent Jefferies India report, the country's CRDMO, which has already reached revenues of around USD 3 billion, has grown at a compound annual growth rate (CAGR) of 14 per cent over the past five years. The report highlights that India's CRDMO industry has caught the ...Read More >
New Delhi: Traffic in central Delhi will be affected on Thursday as the traffic police has issued an advisory due to the Janmashtami and Tazia processions.According to police, the traffic movement in Paharganj is likely to be affected from 1.30pm in view of the shobha yatra for Janmashtami and the Tazia procession.The Janmashtami procession will start from Mandir Shri Banke Bihari Ji in Paharganj's Sangatrasan Bazar and pass through Desh Bandhu Gupta Road, Chuna Mandi, Main Bazar, Munja Chowk an ...Read More >
Cohance Lifesciences will be investing ₹23 crore (₹230 million) in its new Current Good Manufacturing Practice (cGMP) oligonucleotide building block manufacturing facility in Hyderabad. "Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity. This facility is a high-impact strategic investment that complements our pilot and scale-up assets, positioning Cohance to deliver with speed, quality and flexibi ...Read More >
Hyderabad: Cohance Lifesciences Limited, backed by PE giant Advent International, is investing Rs 110 crore in its facilities in Hyderabad and New Jersey. This includes $10 million (approx. Rs 87 crore) in expanding its cGMP bioconjugation capabilities at its US-based subsidiary, NJ Bio, and Rs 23 crore in its new cGMP oligonucleotide building block manufacturing facility in Hyderabad.The new facility in Hyderabad, Cohance said, will enable it to take high-value chemistries like modified nucleos ...Read More >
, /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in from National Medical (TASE:PMCN) Products Administration (NMPA) for the first domestically developed trophoblast cell-surface antigen 2 (TROP2)-directed antibody"drug conjugate (ADC) sacituzumab tirumotecan (sac-™T, formerly SKB264/MK-2870) for adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who ha ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.